Related Experiment Video
Updated: Jun 16, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Impact of comorbidity on complication rates and life expectancy in patients with a leadless pacemaker
Tardu Özkartal1, Alessia D'Alto2, Marco Bergonti1
1Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Insights
Leadless pacemaker implantation is safe in elderly patients, even with high comorbidity. Mortality rates for patients with low comorbidity (CCI ≤ 3) were similar to the general population.
Area of Science:
- Cardiology
- Medical Devices
- Geriatrics
Background:
- Limited data exists on the outcomes of leadless pacemakers (LPM) concerning patient age and comorbidities.
- Understanding these factors is crucial for optimizing patient selection and management.
Purpose of the Study:
- To investigate the outcomes of LPM implantation in relation to patient age and comorbidity status.
- To compare complication rates and mortality between patients with low and high comorbidity levels.
Main Methods:
- A multi-center, retrospective analysis of 863 patients who received LPMs between 2015 and 2022 in Switzerland.
- Patients were stratified by Charlson Comorbidity Index (CCI) into low (≤5) and high (>5) comorbidity groups.
- Outcomes assessed included peri-procedural complications, in-hospital death, and all-cause mortality, with comparisons to the general Swiss population for specific CCI groups.
Main Results:
- No significant difference in peri-procedural or long-term complication rates between low and high comorbidity groups.
- In-hospital mortality was higher in the high-comorbidity group (3.6% vs. 0.6%).
- All-cause mortality was significantly higher in the high-comorbidity group (HR 2.9), with a three-year mortality of 58% compared to 22% in the low-comorbidity group.
Conclusions:
- Leadless pacemaker implantation is a safe procedure in elderly patients, irrespective of high comorbidity, with no increased risk of complications.
- All-cause mortality in LPM patients with a low comorbidity index (CCI ≤ 3) is comparable to the general Swiss population.
- Despite competing risks, LPMs offer a safe pacing solution for elderly individuals with significant comorbidities.
Background:
Knowledge about impact of age and comorbidities on outcome in patients with leadless pacemakers (LPM) is limited.
Objectives:
To analyse outcome in LPM patients according to age and comorbidities.
Methods:
This Swiss, multi-centre, retrospective analysis includes all patients with LPM implanted between 2015 and 2022. Charlson-Comorbidity-Index (CCI) was determined and patients were divided into a low- (CCI ≤ 5) and high-comorbidity (CCI > 5) group. Peri-procedural complications, in-hospital death, and all-cause mortalities were assessed. Finally, all-cause mortality according to three groups (CCI ≤ 3, 4-5, >5) was compared to age and sex-adjusted mortality in the general Swiss population.
Results:
863 patients (median age 81 years, 65% male, 42% with CCI > 5) were included. Peri-procedural/long-term complication rates did not differ between the low- vs. high-comorbidity groups (2.6% vs. 1.7%, p = 0.48 and 1.2% vs. 2.8%, p = 0.12, respectively). In-hospital (3.6% vs. 0.6%, p = 0.002) and all-cause mortality (HR 2.9, 95%CI 2.2-3.8, p < 0.001) were significantly higher in the high-comorbidity group resulting in a three-year mortality of 58% (95%CI 51-65%) vs. 22% (95%CI 17-27%) in the low-comorbidity group. In patients with a CCI ≤ 3, all-cause mortality was comparable to the age- and sex-adjusted mortality of the general Swiss population.
Conclusions:
In elderly patients with high comorbidity, LPM implantation was not associated with increased peri-procedural/long-term complications. All-cause mortality in LPM patients with a CCI ≤ 3 was comparable to age- and sex-adjusted mortality in the general Swiss population. Despite a relatively high three-year mortality due to competing risk factors, LPM implantation is safe, even in elderly patients with high comorbidity.
Condensed Abstract:
In this Swiss, multi-centre, retrospective cohort analysis, 863 patients implanted with a leadless pacemaker were included and divided into a high-comorbidity (with a CCI > 5) and low-comorbidity (with a CCI ≤ 5) group. There was no between group difference in terms of implantation outcomes and peri-operative or long-term complications. Furthermore, all-cause mortality during follow-up in patients with a CCI ≤ 3 was comparable to age- and sex-adjusted mortality in the general Swiss population. These data indicate that LPM implantation is a safe procedure, even in elderly patients with high comorbidity.
More Related Videos
16:40A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Pathophysiology of Heart Failure
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Mechanism of Cardiac Arrhythmias